The Artemisinin Derivative Artemisone Is a Potent Inhibitor of Human Cytomegalovirus Replication
Authors:
- 1 July 2018
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 62 (7)
Abstract
Human cytomegalovirus (HCMV) is a major cause of disease in immunocompromised individuals and the most common cause of congenital infection and neurosensorial disease. The expanding target populations for HCMV antiviral treatment along with the limitations of the currently available HCMV DNA polymerase inhibitors underscore the need for new antiviral agents with alternative modes of action. The antimalarial artemisinin derivative artesunate was shown to inhibit HCMV in vitro yet has demonstrated limited antiviral efficacy in vivo , prompting our search for more potent anti-HCMV artemisinin derivatives. Here we show that the innovative artemisinin derivative artemisone, which has been screened for its activity against malaria parasites in human clinical studies, is a potent and noncytotoxic inhibitor of HCMV. Artemisone exhibited an antiviral efficacy comparable to that of ganciclovir (50% effective concentration, 1.20 ± 0.46 μM) in human foreskin fibroblasts, with enhanced relative potency in lung fibroblasts and epithelial cells. Significantly, the antiviral efficacy of artemisone was consistently ≥10-fold superior to that of artesunate in all cells. Artemisone effectively inhibited both laboratory-adapted and low-passage-number clinical strains, as well as drug-resistant HCMV strains. By using quantitative viral kinetics and gene expression studies, we show that artemisone is a reversible inhibitor targeting an earlier phase of the viral replication cycle than ganciclovir. Importantly, artemisone most effectively inhibited HCMV infection ex vivo in a clinically relevant multicellular model of integral human placental tissues maintained in organ culture. Our promising findings encourage preclinical and clinical studies of artemisone as a new inhibitor against HCMV.Keywords
Funding Information
- Israel Ministry of Health (310998)
- Artemis Therapeutics
- Israel Science Foundation (275 13)
- EC | FP7 | FP7 People: Marie-Curie Actions (316655)
This publication has 39 references indexed in Scilit:
- APOBEC3A Is Upregulated by Human Cytomegalovirus (HCMV) in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV EffectorJournal of Virology, 2017
- Effect of Ganciclovir on IL-6 Levels Among Cytomegalovirus-Seropositive Adults With Critical IllnessJAMA, 2017
- Zika Virus Infects Early- and Midgestation Human Maternal Decidual Tissues, Inducing Distinct Innate Tissue Responses in the Maternal-Fetal InterfaceJournal of Virology, 2017
- Emerging Cytomegalovirus Management Strategies After Solid Organ Transplantation: Challenges and OpportunitiesCurrent Infectious Disease Reports, 2014
- IN VITRO ACTIVITY OF ARTEMISONE COMPARED WITH ARTESUNATE AGAINST PLASMODIUM FALCIPARUMThe American Journal of Tropical Medicine and Hygiene, 2006
- Artemisone—A Highly Active Antimalarial Drug of the Artemisinin ClassAngewandte Chemie International Edition, 2006
- Relative bioavailability of artesunate and dihydroartemisinin: investigations in the isolated perfused rat liver and in healthy Caucasian volunteers.The American Journal of Tropical Medicine and Hygiene, 2002
- Antiviral activity of artesunate towards wild-type, recombinant, and ganciclovir-resistant human cytomegalovirusesJournal of Molecular Medicine, 2001
- Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidationProceedings of the National Academy of Sciences, 2001
- Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma.Journal of Clinical Investigation, 1995